Area of research
Hematology · Immunology
Research interest
Research interests include Complement system in diseases, Blood transfusion and management, Blood groups and transfusion, and Hematopoietic Stem Cell Transplantation.
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial.
Medical, Societal, and Ethical Considerations for Directed Blood Donation in 2025.
Convalescent plasma treatment of B-cell depleted patients with COVID-19: systematic review and individual participant data meta-analysis
Quality indicators for cell collections for immune effector cell and gene therapy: recommendations from the American Society for Apheresis
Reduction of soluble PD-L1 by plasma exchange and radiation therapy in patients with refractory melanoma re-sensitizes to immunotherapy.
Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation.
Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma A Systematic review and meta-analysis
Therapeutic plasma exchange for steroid refractory idiopathic inflammatory myopathies with interstitial lung disease.
Plasma exchange in the intensive care unit: a narrative review
Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma
Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma.
IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients With Angina and Nonobstructive Coronary Arteries.
Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19.
Considerations for immune effector cell therapy collections: a white paper from the American Society for Apheresis
Coagulation profile of human COVID-19 convalescent plasma.
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors.
<scp>COVID</scp>‐19 convalescent plasma: Interim recommendations from the <scp>AABB</scp>
Laboratory Medicine and Pathology Education During the COVID-19 Pandemic-Lessons Learned.
Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients
Report of the <scp>ASFA</scp> apheresis registry study on Wilson's disease